Application

Research CategoryApoptosis & Cancer

Research Sub CategoryGlucose/Glycogen Metabolism

This Anti-PFKFB3 Antibody, clone 4C10.2 is validated for use in Western Blotting, Immunocytochemistry for the detection of PFKFB3.

Immunocytochemistry Analysis: A 1:250 dilution from a representative lot detected PFKFB3 in A431 cells.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (EC 2.7.1.105; EC 3.1.3.46; UniProt Q16875; also known as 6PF-2-K/Fru-2,6-P2ase 3, 6PF-2-K/Fru-2,6-P2ase brain/placenta-type isozyme, iPFK-2, PFK/FBPase 3, Renal carcinoma antigen NY-REN-56) is encoded by the PFKFB3 gene (Gene ID 5209) in human. The homodimeric bifunctional 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFBs) phosphorylate fructose 6-phosphate (F6P) to fructose-2,6-bisphosphate (F2,6BP), which in turn activates 6-phosphofructo-1-kinase and glycolytic flux to lactate. PFKFB3 is distinguished from the other three known PFKFBs (PFKFB1, 2, 4) by the presence of multiple copies of the AUUUA instability motif in its 3′-untranslated region, a very high kinase:phosphatase activity ratio (740:1), increased protein expression in rapidly proliferating transformed cells, solid tumors and leukemias, and regulation by several proteins essential for tumor progression. Heterozygous deletion results in reduced glucose metabolism and growth of Ras-transformed tumors in Pfkfb3+/- mice. PFKFB3 nuclear localization is reported in multiple cell lines due to the presence of a highly conserved C-terminal nuclear localization motif. F2,6BP is reported to enhance cyclin-dependent kinase (Cdk) activity toward p27 Thr187 phosphorylation in vitro, while ectopic expression of PFKFB3 in the nucleus is found to stimulate cellular proliferation without affecting glycolysis, suggesting a novel role of PFKFB3-mediated F2,6BP in cell cycle regulation. The canonical form of human PFKFB3 is a 520-a.a. protein composed of an N-terminal 6-phosphofructo-2-kinase domain (a.a. 1-245) and a C-terminal fructose-2,6-bisphosphatase domain (a.a. 246-520).

Immunogen

Epitope: C-terminal region.

GST-tagged recombinant human PFKFB3 C-terminal fragment.

Other Notes

Concentration: Please refer to lot specific datasheet.

Physical form

Purified mouse monoclonal IgG2aκ antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Protein G purified.

Format: Purified

Quality

Evaluated by Western Blotting in HEK293 cell lysate.

Western Blotting Analysis: 2.0 µg/mL of this antibody detected PFKFB3 in 10 µg of HEK293 cell lysate.

Specificity

The immunogen corresponds the C-terminal fragment of human PFKFB3 spliced isoforms 1, 3, and 4 reported by UniProt (Q16875), cross-reactivity toward spliced isoform 2 is likely, but has not been confirmed.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Target description

~57 kDa observed. 59.61 kDa (isoform 1), 58,88 kDa (isoform 2), 57.29 kDa (isoform 3), 60.60 kDa (isoform 4) calculated. Uncharacterized band(s) may appear in some lysates.